Novelos Therapeutics announced that the University of Wisconsin Carbone Cancer Center has enrolled the first patient in a Phase 1-2 positron emission tomography imaging trial of I-124-CLR1404, a cancer-targeted PET imaging agent, in patients with advanced non-small cell lung cancer.
European stocks rose for a third straight session on Monday and the euro bounced back from two-year lows, as Greek …
There are no comments yet